Companies
Almac
an API chemical-development CDMO running immobilised-lipase (CALB) biocatalysis and cGMP flow-hydrogenation capability for late-stage sponsor process development.
- Country
- United Kingdom
Commercial
Biocatalysis CDMO
Coverage
| CN | EU | US | |
|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Revenue | £1.1 billion | pomanda.com · almacgroup.com |
| Headcount | more than 7,900 employees | almacgroup.com |
| Headquarters | Craigavon, Northern Ireland | almacgroup.com · www3.almacgroup.com |
| Regulatory approval | cGMP compliant flow hydrogenation capability | pharmasource.global · almacgroup.com |
| Production site | 18 facilities in Europe, North America, and Asia | almacgroup.com |
Independent sources: pharmasource.global · pomanda.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Chemoenzymatic API synthesis (biocatalytic small-molecule manufacturing) | therapeutics-platforms | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.